Paeds Vivas · mental-behavioural-and-psychosomatic
Substance intoxication, withdrawal and use disorders in youth — branching viva
Branching viva on separating intoxication, withdrawal and the use disorder, CRAFFT screening, SBIRT stepped care, the buprenorphine pathway, and the cannabis-psychosis link.
On this page
Study tools
Target exams
Opening
Examiner: A 16-year-old is in your clinic with daily cannabis use since age 13, falling school marks, a new and risky peer group, and a CRAFFT screen positive on five items. His parents have read that cannabis causes psychosis and are frightened. How do you frame this assessment? [3]
Candidate: I would treat this as a likely cannabis use disorder within an SBIRT framework. I would take a structured, confidential, multi-informant history — the young person alone for the substance, risk and mental-health history — screen and confirm the diagnosis on DSM-5 criteria, assess mental state and suicide risk, and only then move to a stepped-care plan. I separate three things at every encounter: intoxication, withdrawal and the use disorder. [3]
Branch 1 — diagnosis
Examiner: What DSM-5 criteria make this a use disorder rather than experimentation? [1]
Candidate: A substance use disorder is two or more of eleven criteria in twelve months, drawn from four clusters. He has impaired control (failed efforts to cut down), social impairment (school decline, withdrawal from sport, risky peer group), risky use (driving after using), and pharmacological change (tolerance and a withdrawal syndrome). He meets multiple criteria, so this is at least a moderate disorder — experimentation would not meet the criteria at all. [1]
Examiner (probe): Why not just rely on a urine drug screen? [3]
Candidate: A urine drug screen detects recent exposure to a class of drug; it does not diagnose a use disorder, does not measure impairment, and has false positives and negatives. The diagnosis is clinical, made on criteria from the history. A screen used without consent as surveillance also destroys the therapeutic alliance. [3]
References7ShowHide
- [1]Hasin DS, O'Brien CP, Auriacombe M, et al. DSM-5 criteria for substance use disorders: recommendations and rationale. Am J Psychiatry, 2013.PMID 23903334
- [2]Knight JR, Sherritt L, Shrier LA, Harris SK, Chang G. Validity of the CRAFFT substance abuse screening test among adolescent clinic patients. Arch Pediatr Adolesc Med, 2002.PMID 12038895
- [3]Levy SJ, Williams JF Substance use screening, brief intervention, and referral to treatment. Pediatrics, 2016.PMID 27325634
- [4]Dennis M, Godley SH, Diamond G, et al. The Cannabis Youth Treatment (CYT) study: main findings from two randomized trials. J Subst Abuse Treat, 2004.PMID 15501373
- [5]Waldron HB, Turner CW. Evidence-based psychosocial treatments for adolescent substance abuse. J Clin Child Adolesc Psychol, 2008.PMID 18444060
- [6]Moore THM, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet, 2007.PMID 17662880
- [7]Marsch LA, Moore SK, Borodovsky JT, et al. A randomized controlled trial of buprenorphine taper duration among opioid-dependent adolescents and young adults. Addiction, 2016.PMID 26918564